18:45 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

FDA approves first drug for neurotrophic keratitis

FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare eye disease. Oxervate is the first drug approved in the U.S. for the indication, according to the agency. A...
22:06 , Aug 22, 2018 |  BC Extra  |  Company News

FDA approves first drug for neurotrophic keratitis

FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare eye disease. Oxervate is the first drug approved in the U.S. for the indication, according to the agency. A...
17:24 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to...
21:24 , Aug 16, 2018 |  BC Extra  |  Clinical News

Regeneron, Teva’s anti-NGF mAb meets 16-week endpoints in Phase III for OA pain

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said fasinumab met the co-primary endpoints at week 16 in a substudy of the larger Phase III FACT LTS & OA trial to...
16:19 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) said tanezumab met the three co-primary endpoints compared with placebo in the Phase III A4091056 trial to treat osteoarthritis pain. Pfizer said the data support...
21:41 , Jul 18, 2018 |  BC Extra  |  Clinical News

Pfizer's tanezumab meets in Phase III for OA pain

Pfizer Inc. (NYSE:PFE) and partner Eli Lilly and Co. (NYSE:LLY) said tanezumab met the three co-primary endpoints compared with placebo in the Phase III A4091056 trial to treat osteoarthritis pain. Pfizer said the data support...
16:27 , May 4, 2018 |  BC Week In Review  |  Clinical News

Regeneron halting higher doses in fasinumab trials

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab. Regeneron will modify ongoing trials to continue with two lower doses, President and CSO George...
17:19 , May 3, 2018 |  BC Extra  |  Company News

Regeneron halting higher doses in fasinumab trials

In its 1Q18 earnings, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab (REGN475). Regeneron will modify ongoing trials to continue with two lower...
16:34 , Jan 12, 2018 |  BC Week In Review  |  Company News

Pfizer ending discovery and early neuroscience programs

Pfizer Inc. (NYSE:PFE) said it will terminate its discovery and early development neuroscience programs as a result of a "recent comprehensive review." The pharma estimates the move will result in 300 layoffs "over the coming...
01:03 , Jan 6, 2018 |  BC Extra  |  Company News

Pfizer ending discovery, early neuroscience program

Pfizer Inc. (NYSE:PFE) said Friday it will terminate its discovery and early development neuroscience programs as a result of a "recent comprehensive review." The pharma estimates the move will result in 300 layoffs "over the...